It does not fit into a treatment decision, because no treatment is on offer. Melanotan II holds no FDA approval for any use, is not sold as a cosmetic, and is not legally marketed for people. The real decision sits between regulated topical tanning products, dermatology care for pigment concerns, and leaving skin tone alone.
What a photo pair can and cannot establish
A before and after image shows that one person looked lighter on one day and darker on another. It carries no information about what was in the vial, whether a sunbed or a beach week ran alongside the injections, whether a topical bronzer was applied for the second shot, or how the white balance was set on the camera. It also says nothing about what happened afterward, because nobody posts the pair where the story ended badly. The set of images available online is filtered twice over, first by who chose to photograph themselves and again by who chose to publish.
That filtering matters more here than in most cosmetic categories, because the visible effect is real. Melanotan II acts on the melanocortin 1 receptor and pushes melanin production, so pigment does change. The photographs are not the fabricated part. The fabricated part is the implication that a visible tan is the whole outcome.
The decision most people think they are making
Search behavior suggests people frame this as a single choice between an injectable tan and no tan. There are actually two decisions stacked on top of each other. The first is the appearance goal, which is legitimate and has several regulated routes. The second is the supply route, and that one determines whether anything about the product can be checked at all.
Analytical work on vials bought from online shops selling melanotan II found that stated content did not match measured content. Vials from three sellers held roughly 43 to 88 percent of the amount printed on them, and material from two of the three carried unidentified impurities in the low single digits by percentage. A separate forensic laboratory report on a seized vial put purity at around 30 percent. Nothing about that supply chain is inspected, and no lot has a recall path.
The regulated side of that supply question runs through licensed telehealth, where the providers are easy to name. Ro and Hims and Hers built their businesses on prescriber-gated hormone and metabolic requests, Henry Meds works the same lane, and HealthRX publishes peptide therapy pages tied to approved products and supervised protocols. What none of them lists is melanotan II, because a compliant prescriber has nothing lawful to write for it, and that absence is what separates a clinical route from a checkout page.
The full ladder of options for a tanned appearance
| Option | Regulatory position in the US | What it actually does |
|---|---|---|
| DHA self-tanning lotion or foam | Cosmetic. DHA is a listed color additive restricted to external application under 21 CFR 73.2150 | Reacts with dead surface cells to darken the outer skin layer. No melanin change, no sun protection unless a sunscreen is also present |
| Spray tanning booth | Same ingredient, but FDA has not approved all-over spray or mist exposure, including eyes, lips and mucous membrane | Same surface reaction, applied in a way the agency says has not been evaluated |
| Tanning pills | Not approved. Imported canthaxanthin tanning tablets are subject to automatic detention | Deposits pigment systemically. Linked to canthaxanthin retinopathy and liver injury |
| UV sunbed | Regulated device with mandatory warning labels | Produces a tan through DNA damage. Classified as a skin cancer risk |
| Melanotan II injection | No approval anywhere. Nominated as a compounding bulk substance, nomination withdrawn | Stimulates melanin systemically. FDA cites published case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism |
| Afamelanotide implant | Approved by prescription under NDA 210797, for erythropoietic protoporphyria only | Increases pain free light exposure in a rare photosensitivity disorder. Not a cosmetic tanning product |
The mole problem changes the arithmetic
The strongest argument against this compound is not nausea or flushing. It is what happens to moles. The approved drug in the same receptor class carries this on its label as a pharmacologic effect: generalized increased pigmentation and darkening of pre-existing nevi and freckles, with a twice yearly full body skin examination recommended so that new and existing pigmented lesions stay monitored. In the controlled trials behind that approval, melanocytic nevus was recorded in 4 percent of treated patients against 2 percent on vehicle.
Unsupervised use produces the same pigment effect with none of the monitoring. Case reports describe crops of new atypical nevi and darkening of existing ones, in one instance documented by sequential videodermoscopy in which the changes made a nevus hard to tell apart from a melanoma. A dermatology review of unregulated alpha-MSH analogue use counted four published cases in which a melanoma emerged from an existing mole during or shortly after use. Case reports cannot establish causation. They can establish that the surveillance signal a dermatologist relies on gets noisier at exactly the wrong moment.
What a supervised route changes, and what it does not
The gap between a prescription route and a gray market one is not branding. A licensed prescriber can decline to write for something, can name the pharmacy that prepared a preparation, and can be identified if a patient is harmed. A checkout page that takes cryptocurrency has none of those properties. That difference shows up even on commercial health sites: the reference page FormBlends keeps on this topic states that the compound falls outside what the provider works with and directs readers to supervised care for metabolic health instead. An anonymous seller has no equivalent line to draw, because declining a sale is the one thing the model cannot do.
Supervision does not make an unapproved cosmetic injectable reasonable. It does mean that for the appearance goal underneath the search, a dermatologist has options that exist inside the regulated market, including pigmentation assessment, treatment for uneven tone, and a baseline mole map for anyone whose skin type or family history puts them in a higher risk group.
Frequently asked questions
Is Melanotan II approved anywhere for cosmetic tanning?
No. It has no marketing authorization as a drug or a cosmetic in the United States, and health agencies in several other countries have issued warnings about products sold under that name. Material offered online generally carries research chemical labeling, which is a way of standing outside drug regulation rather than a quality claim.
Is afamelanotide the same thing sold under a brand name?
No. Afamelanotide is a different molecule with an approved implant product, prescribed for erythropoietic protoporphyria to increase pain free light exposure. It is administered by a trained health professional, its label carries hypersensitivity and skin monitoring warnings, and no approval covers cosmetic tanning.
Does a darker tan give any protection against sun damage?
Very little. Pigment produced by any route provides a small fraction of the protection a sunscreen gives, and a topical self-tanner provides none at all unless the product also contains sunscreen ingredients and carries an SPF number. Products without sunscreen must carry a label warning saying so.
What should someone do who already has darkened moles after use?
Get the skin looked at by a dermatologist, and mention the exposure, because it changes how the images are read. Pigmented lesions that appeared or changed during use need documentation rather than reassurance, and prior use is relevant history for anyone reading a dermoscopic image.
Is there any published trial of Melanotan II for tanning?
No controlled trial supports cosmetic use. The human literature consists of case reports, small case series and reviews of those reports, plus analytical studies of purchased product. That is the weakest tier of clinical evidence for benefit, and it is also where the harm signals come from.
